Genetic Literacy ProjectCRISPR paired with DNA barcoding could track cancer growthGenetic Literacy ProjectStanford scientists have found a way to modify pairs of cancer-related genes in the lungs of mice and then precisely track individual cells of the… Continue reading
Genetic Literacy ProjectCRISPR paired with DNA barcoding could track cancer growthGenetic Literacy ProjectStanford scientists have found a way to modify pairs of cancer-related genes in the lungs of mice and then precisely track individual cells of the… Continue reading
Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USAGlobeNewswire (press release)EXTON, Pa., April 10, 2018 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company foc… Continue reading
|
HealthWatch: Fighting Parkinson’s With Deep Sea Shrimp and CRISPR
WeAreGreenBay.com A gene editing system called CRISPR allows them to “light up” a protein in the brain associated with Parkinson’s. Levi Adams, a Doctoral Student at the Burnett School of Biomedical Sciences, said, “In this study we are working with a protein that was … |
Nasdaq |
FOCUS-Lonza’s virus factory shows gene therapy’s Texas-sized promise
Nasdaq ZURICH, April 10 (Reuters) – Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution. The 121-year-old Basel-based contract manufacturer … |
Nasdaq |
FOCUS-Lonza’s virus factory shows gene therapy’s Texas-sized promise
Nasdaq ZURICH, April 10 (Reuters) – Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution. The 121-year-old Basel-based contract manufacturer … |
Reuters |
Lonza’s virus factory shows gene therapy’s Texas-sized promise
Reuters But the Association of the British Pharmaceutical Industry estimates the global cell and gene therapy market will be worth up to $21 billion annually by 2025. Pharmaceutical and biotechnology companies are racing to develop therapies that rely on … |